tiprankstipranks
Advertisement
Advertisement

Everest Medicines Expands Shareholder Base with Strategic Share Disposal

Story Highlights
  • Everest Medicines Ltd. focuses on transformative pharmaceutical products and innovative treatments.
  • CBC Group plans to sell 25 million shares to broaden Everest Medicines’ shareholder base.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Everest Medicines Expands Shareholder Base with Strategic Share Disposal

Elevate Your Investing Strategy:

An announcement from Everest Medicines Ltd. ( (HK:1952) ) is now available.

Everest Medicines Ltd. announced that its controlling shareholder, CBC Group, plans to sell 25,000,000 shares, representing approximately 7.63% of the company’s issued share capital, to global long-only and healthcare specialist investors. This move aims to broaden the company’s shareholder base with high-quality investors to support its long-term growth. The company remains committed to its strategic focus areas, including increasing sales of its key products, advancing regulatory processes, and developing next-generation treatments, without any material changes to its business operations or financial position.

The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.

More about Everest Medicines Ltd.

Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products. The company is engaged in the sale of NEFECON®, a unique drug for IgAN, and XERAVA®, an antibiotic, while also advancing regulatory processes for VELSIPITY® and developing innovative treatments like mRNA cancer vaccines and in-vivo CAR-T programs.

Average Trading Volume: 5,353,387

Technical Sentiment Signal: Buy

Current Market Cap: HK$17.93B

See more insights into 1952 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1